GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MindBio Therapeutics Corp (FRA:WF6) » Definitions » Notes Receivable

MindBio Therapeutics (FRA:WF6) Notes Receivable : €0.00 Mil (As of Mar. 2025)


View and export this data going back to 2023. Start your Free Trial

What is MindBio Therapeutics Notes Receivable?

MindBio Therapeutics's Notes Receivable for the quarter that ended in Mar. 2025 was €0.00 Mil.


MindBio Therapeutics Notes Receivable Historical Data

The historical data trend for MindBio Therapeutics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MindBio Therapeutics Notes Receivable Chart

MindBio Therapeutics Annual Data
Trend Jun21 Jun22 Jun23 Jun24
Notes Receivable
- - - -

MindBio Therapeutics Quarterly Data
Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

MindBio Therapeutics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


MindBio Therapeutics Notes Receivable Related Terms

Thank you for viewing the detailed overview of MindBio Therapeutics's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


MindBio Therapeutics Business Description

Traded in Other Exchanges
Address
91-97 William Street, Level 4, Melbourne, VIC, AUS, 3000
MindBio Therapeutics Corp is engaged in the research, development, and testing of psychedelic substances as a potential treatment for the management of a broad range of mental health conditions. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough micro dosing studies. Geographically, the company's activities take place in Australia.

MindBio Therapeutics Headlines

No Headlines